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Mutation of Membrane Type-1 Metalloproteinase,
MT1-MMP, Causes the Multicentric Osteolysis
and Arthritis Disease Winchester Syndrome
Brad R. Evans,1,5 Rebecca A. Mosig,1,5 Mollie Lobl,1 Chiara R. Martignetti,1 Catalina Camacho,1
Valerie Grum-Tokars,2,6 Marc J. Glucksman,2 and John A. Martignetti1,3,4,*
The ‘‘vanishing bone’’ syndromes represent a group of rare skeletal disorders characterized by osteolysis and joint destruction, which can
mimic severe rheumatoid arthritis. Winchester syndrome was one of the first recognized autosomal-recessive, multicentric forms of the
disorder. It was originally described nearly 50 years ago in two sisters with a severe crippling osteolysis. Using cultured fibroblasts from
the proband, we have now identified homozygous mutations in membrane type-1 metalloproteinase (MT1-MMP or MMP14). We
demonstrate that the resulting hydrophobic-region signal-peptide substitution (p.Thr17Arg) decreases MT1-MMP membrane localiza-
tion with consequent impairment of pro-MMP2 activation, and we propose a structure-based mechanism for this effect.The inherited osteolyses, or ‘‘vanishing bone’’ syndromes,
represent a group of genetically heterogeneous syndromes
that primarily affect the bones and joints and that are
clinically distinguished on the basis of anatomical distribu-
tion, severity, associated syndromic features, and inheri-
tance patterns. Given their rarity and clinical overlap,
exact diagnosis can be difficult. Identifying the genes and
pathways that underlie these inherited syndromes has
the potential to provide not only a defining molecular
diagnostic for each but also insight into the pathogenic
mechanisms that result in these disorders and the more
common, sporadic forms of osteoporosis, osteolysis, and
arthritis.
The first of these Mendelian disorders to be geneti-
cally defined was multicentric osteolysis, nodulosis, and
arthropathy (MONA [MIM 259600]), which results from
protein-inactivating mutations in MMP2.1 The then
‘‘counterintuitive’’ finding that loss of a gelatinase and/or
collagenase would result in bone loss and joint destruction
provided the first genetic evidence linking extracellular-
matrix proteolysis with human growth and skeletal devel-
opment.2 These findings also highlighted what appeared
to be species differences between loss of MMP function
in humans and mice. Specifically, Mmp2-null mice had
been reported as being overtly phenotypically normal,3
whereas knockout of the metalloproteinase MT1-MMP,
which functions in part as a pericellular activator of
MMP-2, resulted in mice that had generalized skeletal
defects more severe than those associated with MONA
and that suffered from wasting and decreased survival.4
Since then, a MONA-like progressive osteolysis and arthri-
tis phenotype has been demonstrated in Mmp2-knockout
mice.5 On the other hand, no human disease has been
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572 The American Journal of Human Genetics 91, 572–576, SeptembWinchester syndrome is a presumed autosomal-recessive
disorder first described in two sisters who had severe
skeletal and joint deformities and whose unaffected,
healthy parents were first cousins.6 The children suffered
from progressive bilateral and symmetric osteolysis of
the carpals and tarsals, interphalangeal joint erosions
mimicking rheumatoid arthritis, generalized osteoporosis,
and eventual loss of function of the larger joints, including
the shoulder, elbow, hip, and knee joints (Figure 1A). It
was also noted that the siblings had gum hypertrophy,
corneal opacities, and electrocardiographical findings sug-
gestive of myocardial damage.6 MONA and Winchester
syndromes have been grouped together as allelic disorders
on the basis of their phenotypic overlap and the discovery
of MMP2 mutations in two recently diagnosedWinchester
families (reviewed in Mosig et al.8). Despite this presumed
shared genetic etiology, the primary and associated fea-
tures of the two syndromes nonetheless seemed distinct
enough to us (on the basis of their original descriptions)
to warrant a genetic analysis of the Winchester syndrome
proband first described in 1969.
We therefore obtained primary cultured fibroblasts that
had been established from one of the two Winchester
probands (GM02295, Coriell Institute). We began our
molecular characterization by analyzing first the biochem-
ical activity and then the gene sequence of MMP2. Condi-
tioned media from these fibroblasts had abundant levels
of MMP-2 proenzyme but reduced MMP-2 activity (Fig-
ure 1B). This is in marked contrast to MONA-derived cell
lines, which do not show zymographic activity of either
the proenzyme or active forms of MMP-2.1 Furthermore,
when we isolated genomic DNA from this patient-derived
cell line, we were unable to identify mutations in either the
exons or intron-exon boundaries of MMP2.dicine, New York, NY, USA; 2Department of Biochemistry and Molecular
edical School, North Chicago, IL, USA; 3Department of Pediatrics, Mount
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Figure 1. Identification of an MT1-MMP
Mutation in Winchester Syndrome
(A) Radiographs of the hand and skull of
the affected proband, aged 18 years. The
hand radiograph demonstrates complete
loss of all carpal bones, destructionofmeta-
carpals andphalanges, and severe ankylosis
of the remaining bones. The skull radio-
graph demonstrates the generalized nature
of the osteolytic loss of bone and that the
anterior fontanelle remains patent.
(B) Gelatin zymogram of conditioned
medium from primary fibroblasts. Lane 3
shows lessMMP2activation inconditioned
medium from Winchester cells than do
lanes 1 and 2, which are medium from
control cells (AG060062 and GM17071A,
respectively).
(C) Chromatograms showing C50G trans-
version in Winchester DNA, but not in
control DNA.
(D) Missense mutation results in a T>R
replacement in the predicted hydrophobic
region of the signal peptide.7Although we could not rule out the possibility of either
undetected promoter or intronic mutations, we hypothe-
sized that loss of an upstream MMP-2 protein activator,
such as MT1-MMP, could also result in decreased MMP-2
activity without affecting MMP2. Our interest in this
enzyme as a potential disease candidate was based not
only on an appreciation of the skeletal phenotype of the
Mt1-mmp-null mouse4 but also on the fact that tissues
derived from the Mt1-mmp-null mouse have an impaired
ability to activate MMP-2.7 However, it should be noted
that MT1-MMP is not the sole membrane-type MMP re-
sponsible for MMP-2 activation, and therefore, some level
of MMP-2 activation might exist even in the absence of
MT1-MMP activity. We therefore sequenced MT1-MMP
(RefSeq accession number NM_004995.2) in these fibro-
blasts. Sequence analysis revealed a homozygous missense
mutation, a C>G transversion (n.284C>G) in codon 17 of
exon 1, that predicted replacement of a threonine by an
arginine (p.Thr17Arg) (Figure 1C). The mutation was not
present in the db132 or 1000 Genomes databases or in
an additional 100 Puerto Rican control chromosomes that
we screened (data not shown).
Intriguingly, the mutation occurs in the hydrophobic
domain of MT1-MMP’s signal peptide (Figure 1D). As a first
step in exploring the possible pathogenicity of this muta-
tion, we used the program SignalP 4.09 to compare the
wild-type (WT) and altered signal-peptide sequences. The
in silico analysis suggested that the mutation might have
a functional consequence because the cleavage-site score
of the altered protein was lower (8.0) than that of the
WT sequence (9.2).
Wishing to explore this further, we then analyzed
the altered MT1-MMP in the patient-derived fibroblasts.
Immunoblot of whole-cell lysates revealed thatWinchester
fibroblasts had dramatically lower levels of proenzyme and
active forms of MT1-MMP than did control primary fibro-
blasts (Figure 2A). There were no concomitant decreasesThe Americanin MT1-MMP mRNA expression levels in Winchester cells
compared to controls 1 and 2 (relative values of 1.00,
0.45, and 0.79, respectively) (Figure S1, available online).
BecauseMT1-MMP functionality requires membrane local-
ization and given that the signal peptide sequence is
necessary for defining a protein’s correct subcellular locali-
zation and function, we next examined altered protein
levels at the membrane surface. We used two comple-
mentary techniques: membrane fractionation and surface
biotinylation. Unlike control cells and despite the protein’s
presence in the cytoplasmic fraction, Winchester fibro-
blasts had almost no detectable levels of active MT1-MMP
either in the membrane fraction (Figure 2B) or on their
surface (Figure 2C).
Because improperly transported membrane or secreted
proteins would be expected to be targeted for rapid degra-
dation, we then investigated the stability of altered MT1-
MMP. Transient transfections with expression constructs
containing either WT or mutantMT1-MMP in COS-7 cells,
which do not express endogenous MT1-MMP, resulted in
a >100-fold increase inMT1-MMPmRNA expression levels
(Figure S2A). As noted with the endogenous altered MT1-
MMP in patient-derived fibroblasts (Figure 2A), the proen-
zyme and active forms of altered MT1-MMP were both
considerably lower than WT levels in transfected cells
(Figure S2B). In addition, cells expressing altered MT1-
MMP had noticeably lower amounts of active MMP-2 in
their conditioned media (Figure S3A). We then treated
the transfected cells with the protein-synthesis inhibi-
tor cycloheximide. Compared with the WT protein, the
altered protein was quickly degraded (Figure 3A). Blocking
proteasomal degradation with MG-132 increased the
amount of altered proenzyme, but the active form of
altered MT1-MMP remained undetectable (Figure 3B).
MG-132 had no effect on WT or mutant MT1-MMP
mRNA expression levels (Figure S3B). All together, the
experiments on the altered protein demonstrated theJournal of Human Genetics 91, 572–576, September 7, 2012 573
Pro-MT1-MMP
Active MT1-MMP
GAPDH
70 -
kDa:
55 -
Co
ntr
ol 
1
Co
ntr
ol 
2
W
inc
he
ste
r
CYTOPLASMIC MEMBRANE
Pro-MT1-MMP
Active MT1-MMP
Co
ntr
ol 
1
Co
ntr
ol 
2
W
inc
he
ste
r
Pan Cadherin
GAPDH
70 -
kDa:
55 -
Co
ntr
ol 
1
Co
ntr
ol 
2
W
inc
he
ste
r
Pro-MT1-MMP
Active MT1-MMP
Pan Cadherin
Co
ntr
ol 
1
Co
ntr
ol 
2
W
inc
he
ste
r
70 -
kDa:
55 -
A
B
C
Figure 2. Winchester Mutation De-
creases Active Form of MT1-MMP
(A) Immunoblot analysis of whole-cell
lysates (30 mg) showed a ~78% reduction
in proenzyme and a ~42% reduction in
active enzyme in Winchester-patient-
derived primary fibroblasts (relative proen-
zyme value ¼ 1; relative active value ¼ 1)
compared to control primary fibroblasts
AG060062 (proenzyme value ¼ 5.3; active
value ¼ 2) and GM17071A (proenzyme
value ¼ 3.8; active value ¼ 1.4).
(B) Immunoblot of cellular fractionation
of primary cells (30 mg) shows no detect-
able active form of MT1-MMP in the
membrane fraction of Winchester cells.
Densitometric analysis of proenzyme
between Winchester and control cells
(AG060062 and GM17071A) shows
comparable levels in the cytoplasmic
fraction (the ratio of Winchester cells to
AG060062 is 1.0 to 1.1, and the ratio of
Winchester cells to GM17071A is 1.0 to
0.89). However, there is an increase in
MT1-MMP proenzyme in the membrane
fraction (the ratio of Winchester cells to
AG060062 is 1.0 to 2.0, and the ratio
of Winchester cells to GM17071A is 1.0
to 1.1.
(C) Immunblot of cell-surface-isolated
MT1-MMP. Biotin labeling and isola-
tion of cell-surface proteins show that
Winchester cells lack the active form of
MT1-MMP and have lower levels of the
proenzyme than do control cells (the ratio
of Winchester cells to AG060062 is 1.0 to
2.3, and the ratio of Winchester cells to
GM17071A is 1.0 to 1.4).deleterious effect of the mutation on subcellular localiza-
tion, protein stability, and MMP-2 activation.
Mutations in the signal-peptide region have been pre-
viously associated with a number of human diseases
(reviewed in Jarjanazi et al.10). One difficulty in assessing
pathogenicity on the sole basis of sequence analysis is
that no consensus sequence has been defined for the sig-
nal peptide. They are highly variable in both their length
and amino acid sequence composition. Nonetheless,
all sequences contain a tripartite domain structure that
has a conservative motif ensemble: a positively charged
amino N terminus, a middle hydrophobic H region con-
taining 8–20 hydrophobic residues, and a polar carboxyl
C terminus. The signal recognition particle (SRP) recog-
nizes this nascent sequence as translated proteins emerge
from the ribosome and shuttles these proteins to the endo-
plasmic reticulum. We hypothesized that the Winchester
mutation could affect recognition and binding of the
MT1-MMP signal peptide to the SRP complex. Recently,
a high-resolution crystallographic structure of the SRP54
protein component of the SRP interacting with a signal
peptide (Protein Data Bank ID 3KL4, Research Collabora-574 The American Journal of Human Genetics 91, 572–576, Septembtory in Structural Bioinformatics) was solved, allowing
for the high-resolution visualization of the molecular
recognition sites between the protein and peptide.11 We
thereby sought to ascribe a structural correlate to the
aberrant function caused by the Winchester mutation.
Residues in the H region of the signal peptide—the same
region in which we identified the Winchester mutation—
reside in the hydrophobic groove of the SRP.11 We aligned
the motifs first and then the sequence. In the crystal struc-
ture near the interface beyond the hydrophobic region,
there is a threonine residue (position 459) that we mutated
to arginine in silico with energy minimization and subse-
quently modeled with the calculated rotamer. The crystal
structure of the bound peptide demonstrates a ‘‘ridges
and grooves’’ packing between the helices (Figure 4). Re-
placing the polar, uncharged threonine with the large,
charged arginine residue at this position appears to dis-
rupt packing of the H domain of signal sequence to the
M alpha helical domain of the protein. Therefore, we
hypothesize that the ability of mutated MT1-MMP sig-
nal peptide to interact with the SRP is destabilized and
therefore results in inadequate transport and, ultimately,er 7, 2012
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Figure 3. Winchester Mutation Reduces
Protein Stability
Transient transfections in COS-7 cells were
performed with expression constructs for
WT MT1-MMP and Winchester altered
MT1-MMP.
(A) Increased protein turnover in Win-
chester MT1-MMP-transfected cells (40 mg)
incubated with 50 mg/ml cycloheximide
(CHX).
(B) MG-132 treatment increases levels of
the proenzyme form of MT1-MMP, but
not of the active form in Winchester
MT1-MMP-transfected cells (30 mg).loss of MT1-MMP’s necessary targeting to the plasma
membrane.
We now report that an inactivating homoallelic muta-
tion of MT1-MMP in humans results in Winchester syn-
drome, a rare osteolysis and arthritis disorder whose skel-
etal phenotype, although not as severe, parallels those
previously described for the Mt1-mmp-null mouse.4 The
low level of active MT1-MMP present at the surface of
patient-derived fibroblasts provides evidence of at least
partial activity of the enzyme andmight explain the differ-
ences in skeletal findings and survival between affected hu-
mans and engineered Mt1-mmp-null mice. Extrapolating
from the mouse model, we would therefore suggest that
the diagnosis of Winchester syndrome be considered partFigure 4. Winchester Mutation Interferes with MT1-MMP
Interaction with the SRP
Molecular representation of the altered p.Thr17Arg Winchester
superimposed on the Thr479 residue of the signal peptide on
the basis of the X-ray crystallographic structure (Protein Data
Bank ID 3KL4; Janda et al.11) for a signal peptide (blue ribbon back-
bone with space-filling residues) in a ‘‘ridge and groove’’ packing
between helices with the SRP (gray ribbon backbone). On the
left is the closely packed Thr459 wild-type. On the right is the
p.Arg459 alteration disrupting the packing (arrow) of the signal
sequence to the a-helical M4 domain protein. The figure was
rendered in PyMol (v.1.5, Schrodinger, NY, NY).
The Americanof the differential diagnosis for children with osteolysis
and arthritis and early lethality. Similarly, and on the basis
of the original shared finding in theWinchester probands6
and its clinical relevance, all individuals suspected to be
affected by Winchester syndrome and/or MONA should
undergo a complete cardiac evaluation.
Previously, and on the basis of an incorrect clinical
diagnosis of Winchester syndrome, Winchester syndrome
and MONA were presumed to be allelic disorders arising
from mutations in the same gene (reviewed in Mosig
et al.8). Our studies now demonstrate that mutations
in MMP2 and MT1-MMP result in related but distinct
‘‘vanishing bone’’ syndromes. The molecular mechanisms
underlying these phenotypes and associations (if any)
between substrates or pathways will need to be established.
For example, although it is known that mouse fibroblasts
lacking MT1-MMP are defective in their ability to
degrade type I collagen,4 this will need to be experimen-
tally established for human cells. All together, these
studies highlight the difficulty in clinically distinguishing
between two genetically independent MMP-based disor-
ders. Ultimately, these findings extend the range of known
MMPs involved in osteolytic and arthritic disease and
should provide the basis for an increased understanding
of the in vivo function of MT1-MMP in both health and
disease.Supplemental Data
Supplemental Data include Supplemental Material and Methods
and three figures and can be found with this article online at
http://www.cell.com/AJHG.Acknowledgments
The authors thank Patricia Winchester for her thoughtful insights
and the radiographs used in this manuscript.Journal of Human Genetics 91, 572–576, September 7, 2012 575
Received: January 31, 2012
Revised: June 10, 2012
Accepted: July 26, 2012
Published online: August 23, 2012Web Resources
The URLs for data presented herein are as follows:
ImageJ quantification software, http://rsbweb.nih.gov/ij/
Online Mendelian Inheritance in Man (OMIM), http://www.
omim.org
Protein Data Bank, http://www.rcsb.org/pdb/home/home.do
SignalP 4.0, http://www.cbs.dtu.dk/services/SignalP/References
1. Martignetti, J.A., Aqeel, A.A., Sewairi, W.A., Boumah, C.E.,
Kambouris, M., Mayouf, S.A., Sheth, K.V., Eid, W.A.,
Dowling, O., Harris, J., et al. (2001). Mutation of the
matrix metalloproteinase 2 gene (MMP2) causes a multi-
centric osteolysis and arthritis syndrome. Nat. Genet. 28,
261–265.
2. Vu, T.H. (2001). Don’t mess with the matrix. Nat. Genet. 28,
202–203.
3. Itoh, T., Ikeda, T., Gomi, H., Nakao, S., Suzuki, T., and Ito-
hara, S. (1997). Unaltered secretion of beta-amyloid precursor
protein in gelatinase A (matrix metalloproteinase 2)-deficient
mice. J. Biol. Chem. 272, 22389–22392.
4. Holmbeck, K., Bianco, P., Caterina, J., Yamada, S., Kromer, M.,
Kuznetsov, S.A., Mankani, M., Robey, P.G., Poole, A.R., Pidoux,
I., et al. (1999). MT1-MMP-deficient mice develop dwarfism,576 The American Journal of Human Genetics 91, 572–576, Septembosteopenia, arthritis, and connective tissue disease due to
inadequate collagen turnover. Cell 99, 81–92.
5. Mosig, R.A., Dowling, O., DiFeo, A., Ramirez, M.C., Parker,
I.C., Abe, E., Diouri, J., Aqeel, A.A., Wylie, J.D., Oblander,
S.A., et al. (2007). Loss of MMP-2 disrupts skeletal and cranio-
facial development and results in decreased bone mineraliza-
tion, joint erosion and defects in osteoblast and osteoclast
growth. Hum. Mol. Genet. 16, 1113–1123.
6. Winchester, P., Grossman, H., Lim, W.N., and Danes, B.S.
(1969). A new acid mucopolysaccharidosis with skeletal defor-
mities simulating rheumatoid arthritis. Am. J. Roentgenol.
Radium Ther. Nucl. Med. 106, 121–128.
7. Zhou, Z., Apte, S.S., Soininen, R., Cao, R., Baaklini, G.Y.,
Rauser, R.W., Wang, J., Cao, Y., and Tryggvason, K. (2000).
Impaired endochondral ossification and angiogenesis in
mice deficient in membrane-type matrix metalloproteinase I.
Proc. Natl. Acad. Sci. USA 97, 4052–4057.
8. Mosig, R.A., Dowling, O., andMartignetti, J.A. (2008). Human
MMP-2 Deficiency: The Multicentric Osteolysis with Nodulo-
sis and Arthritis (MONA) and Winchester Syndromes. In
Inborn Errors of Development: TheMolecular Basis of Clinical
Disorders of Morphogenesis, 2nd edition, C.J. Epstein, R.P.
Erickson, and A. Wynshaw-Boris, eds. (New York: Oxford
University Press), pp. 1453–1461.
9. Petersen, T.N., Brunak, S., von Heijne, G., and Nielsen, H.
(2011). SignalP 4.0: Discriminating signal peptides from trans-
membrane regions. Nat. Methods 8, 785–786.
10. Jarjanazi, H., Savas, S., Pabalan, N., Dennis, J.W., and Ozcelik,
H. (2008). Biological implications of SNPs in signal peptide
domains of human proteins. Proteins 70, 394–403.
11. Janda, C.Y., Li, J., Oubridge, C., Herna´ndez, H., Robinson,
C.V., and Nagai, K. (2010). Recognition of a signal peptide
by the signal recognition particle. Nature 465, 507–510.er 7, 2012
